Asma Khalid

President-elect Donald Trump has vowed to roll back some of President Biden's signature policies. Here's what Trump's victory means for Biden policies on climate, the civil service and Ukraine.

In this file photo from last year's G20 meeting in New Delhi on Sept. 9, 2023, President Biden speaks with Saudi Crown Prince Mohammed bin Salman and India's Prime Minister Narendra Modi

LIMA, Peru — President Biden will meet with Chinese President Xi Jinping on Saturday on the sidelines of the APEC summit in Lima, Peru, a senior U.S. administration official told reporters on Wednesday.

President Biden is in Lima, Peru, where he's meeting with leaders from the Asia-Pacific region, including Chinese President Xi Jinping. It's expected to be their final meeting.

President Biden is having his final meeting with Chinese President Xi Jinping on Saturday. Biden is in South America attending the last big global summits of his presidency.

President Biden shakes hands with Chinese President Xi Jinping on the sidelines of the Asia-Pacific Economic Cooperation (APEC) summit in Lima, Peru, on Nov. 16, 2024.

"Some may seek to deny or delay the clean energy revolution that's underway in America, but nobody — nobody — can reverse it," Biden said. But Trump has vowed to roll back those plans.

President Biden tours the Museu da Amazonia, a rainforest preserve in Manaus, Brazil, on Nov. 17, 2024, before heading to Rio de Janeiro for the G20 Summit.

“Some may seek to deny or delay the clean energy revolution that’s underway in America, but nobody — nobody — can reverse it,” Biden said. But Trump has vowed to roll back those plans.

Chronic kidney disease (CKD) has shown a growing association with osteoporosis, comprising part of the broader CKD-mineral and bone disorder (CKD-MBD). CKD-MBD is marked by alterations in calcium, phosphorus, parathyroid hormone (PTH), and vitamin D metabolism, significantly elevating fracture risk. While traditional osteoporosis treatments such as bisphosphonates, denosumab, and teriparatide have been adapted for CKD patients, recent innovations have introduced agents aimed at enhancing bone mass and reducing fracture incidence. This study aims to evaluate the pathophysiology, diagnostic methods, and tailored management strategies for osteoporosis in CKD patients. A detailed review of the literature was conducted, involving an in-depth search of PubMed, Medical Literature Analysis and Retrieval System Online (MEDLINE), and the Cochrane Library databases for studies published between 2017 and 2024. Studies were selected based on inclusion criteria focusing on CKD-related osteoporosis, diagnostic criteria, and treatment outcomes. Data extraction and quality assessment were independently performed by multiple reviewers to ensure thoroughness and reduce bias. Findings highlight that conventional treatments, such as bisphosphonates, denosumab, and teriparatide, when tailored to CKD stages, demonstrate variable effectiveness in lowering fracture risk.Additionally, emerging pharmacologic agents hold promise in improving bone density, though evidence on these newer therapies remains limited. Osteoporosis management in CKD patients necessitates a personalized approach guided by the disease's stage and individual profile. This review underscores the potential of emerging therapies and emphasizes the need for further research to refine treatment protocols, aiming to enhance patient outcomes in this complex population.